| [1] |
Bayraktar S, Batoo S, Okuno S, et al. Immunotherapy in breast cancer[J]. J Carcinog，2019，18：2.
|
| [2] |
Zhang J, Tian Q, Zhang M, et al. Immune-related biomarkers in triple-negative breast cancer[J]. Breast Cancer，2021，28(4)：792-805.
|
| [3] |
Zhao J, Huang J. Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1[J]. Chin Med J (Engl)，2020，133(7)：853-862.
|
| [4] |
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer[J]. N Engl J Med，2018，379(22)：2108-2121.
|
| [5] |
Schmid P, Adams S, Rugo HS, et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC) [J]. J Clin Oncol，2019，37(15_suppl)：1003.
|
| [6] |
Emens LA, Adams S, Barrios CH, et al. LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer[J]. Ann Oncol，2020，31：S1148.
|
| [7] |
Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer[J]. Ann Oncol，2021，32(8)：994-1004.
|
| [8] |
Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet，2020，396(10 265)：1817-1828.
|
| [9] |
Cortes J, Cescon DW, Rugo HS, et al. LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC[J]. Ann Oncol，2021，32：S1289-1290.
|
| [10] |
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer[J]. N Engl J Med，2020，382(9)：810-821.
|
| [11] |
Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer[J]. N Engl J Med, 2022, 386(6)：556-567.
|
| [12] |
Li C, Shao Z, Wang Z, et al. Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study[J]. J Clin Oncol，2021，39(15_suppl)：1007.
|
| [13] |
Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer[J]. N Engl J Med, 2022，387(3)：217-226.
|
| [14] |
Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial[J]. Lancet Oncol，2019，20(3)：371-382.
|
| [15] |
Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial[J]. Lancet Oncol，2020，21(10)：1283-1295.
|
| [16] |
Andersson A, Bergenstråhle J, Asp M, et al. Single-cell and spatial transcriptomics enables probabilistic inference of cell type topography[J]. Commun Biol，2020，3(1)：565.
|
| [17] |
Bianchini G, Wang X, Danenberg E, et al. Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial[J]. Cancer Res, 2022, 82(4_Supplement): GS1-00.
|
| [18] |
Dugo M, Huang C, Egle D, et al. Predictive value of RT-qPCR 27-gene IO score and comparison with RNA-Seq IO score in the NeoTRIPaPDL1 trial[J]. Cancer Res, 2022, 82 (4_Supplement): PD10-06.
|
| [19] |
Nielsen TJ, Ring BZ, Seitz RS, et al. A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies[J]. Heliyon，2021，7(3)：e06438.
|